At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
LY3857210 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Osteoarthritis Pain
In Brief
A Phase 2 clinical trial evaluating LY3857210 and Placebo for Osteoarthritis. Completed, enrolled 147 participants across 30 sites in 2 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedNov 2022
Enrollment StartNov 2022
Primary CompletionJun 2023
Study CompletionJun 2023
TodayJul 2026
First PostedNov 17, 2022
Enrollment StartNov 22, 2022
Primary CompletionJun 5, 2023
Study CompletionJun 12, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.6 years ago
Interventions
LY3857210drug
Administered orally
Placebodrug
Administered orally